Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

Blog

Displaying 1 to 10 of 99 Posts . Displaying 10 of Posts . Page of 10 . Go To Page: . Per Page: . . . View All Sort By: .

Video Series on IPC’s Psoriasis Severity Reclassification

Learn how psoriasis severity is currently measured and why a change is necessary, how IPC organized the Delphi process that was used to redefine severity classification, implications and effects the output has on psoriasis treatment providers and psoriasis patients, and ultimately how patients will benefit from this endeavor.

Read More

Janssen Phase-3 TREMFYA® Clinical Trial

Janssen Pharmaceutical Companies of Johnson & Johnson published the long-term data of the third phase of the DISCOVER-2a study.

Read More

Sun Pharma Phase-3 ILUMYA® Clinical Trial

Sun Pharmaceutical Industries Inc. announces results from their five-year Phase-3 efficacy and safety clinical trial for ILUMYA®(tildrakizumab-asmn) based on a pooled analysis of the ReSURFACE 1 and ReSURFACE 2 extension.

Read More

Update on PsoProtect Registry Data

Update on the PsoProtect Registry. PsoProtect is a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis. Data set currently includes 1002 cases.

Read More

New Corporate Member: Dermavant

IPC welcomes Dermavant as a new 2021 corporate member.

Read More

New IPC councilor

Satveer Mahil joins the group of IPC experts who are working to advance knowledge and enhance the care psoriasis patients.

Read More

Commentary: Genetic studies suggest that inflammatory skin diseases increase the risk of COVID-19.

Professor Francesca Capon provides a commentary An article recently published in the Journal of Allergy and Clinical Immunology1 suggests that diseases such as psoriasis and atopic dermatitis increase the risk of COVID-19 by approximately 50%.

Read More

In the Lab with IPC Councilor Nicole Ward

Dr. Ward is a Professor of Dermatology and Neurosciences at Case Western Reserve University and University Hospitals Case Medical Center in Cleveland, Ohio. She has spent the past 16 years developing mouse models to help identify the cellular and molecular mechanisms underlying inflammatory skin disease and its associated comorbidities.

Read More

Commentary: Cytokine inhibitors have a low prevalence of SARS-CoV-2 seroconversion

n a recent publication in Nature Communications1 a team from Friedrich-Alexander University in Germany described their findings from a cross-sectional population cohort study on the prevalence of anti-SARS-CoV-2 immunoglobulin G (IgG) in patients with chronic immune-mediated inflammatory diseases (IMIDs) on cytokine-blocking treatments. This patient cohort was compared against subjects with IMIDs, not on cytokine inhibitors, health care workers, and healthy controls. The findings from this study showed that patients with IMID on cytokine inhibitors had a lower prevalence of anti-SARS-CoV-2 IgG response compared to the other three cohorts. To assess whether this could be accounted for by differences in social exposure between the groups, the investigators assessed exposure risk variables in the four groups and found those to be similar between the two IMID groups and less than that of health care workers.

Read More

Introducing the IPC Academy Online

IPC Academy Online, a free online learning platform, has been designed to provide expert insight, timely research, and practical information to dermatologists anywhere in the world to improve the care of psoriasis patients.

Read More

Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.
SUBSCRIBE

now available

COVID-19 Psoriasis Resource Center

Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve

explore now

 

We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK